Theranostics 2019; 9(19):5694-5705. doi:10.7150/thno.35300
ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease
1. Department of Pediatrics
2. Children's Heart Research and Outcomes Center
3. Molecular and Systems Pharmacology Program
4. Biochemistry, Cell Biology and Developmental Biology Program, Emory University School of Medicine, Atlanta, GA, USA
5. Graduate School of International Agricultural Technology and Institute of Green-Bio Science and Technology, Seoul National University, 1447 Pyeongchang-daero, Pyeongchang, Gangwon-do 25354, South Korea
*These authors equally contributed to this work.
Lee DH, Kim TM, Kim JK, Park C. ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease. Theranostics 2019; 9(19):5694-5705. doi:10.7150/thno.35300. Available from http://www.thno.org/v09p5694.htm
Cardiovascular diseases have long been the leading cause of mortality and morbidity in the United States as well as worldwide. Despite numerous efforts over the past few decades, the number of the patients with cardiovascular disease still remains high, thereby necessitating the development of novel therapeutic strategies equipped with a better understanding of the biology of the cardiovascular system. Recently, the ETS transcription factor, ETV2 (also known as ER71), has been recognized as a master regulator of the development of the cardiovascular system and plays an important role in pathophysiological angiogenesis and the endothelial cell reprogramming. Here, we discuss the detailed mechanisms underlying ETV2/ER71-regulated cardiovascular lineage development. In addition, recent reports on the novel functions of ETV2/ER71 in neovascularization and direct cell reprogramming are discussed with a focus on its therapeutic potential for cardiovascular diseases.
Keywords: ER71/ETV2, FLK1/VEGFR2, cardiovascular, angiogenesis, direct cell reprogramming